Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 569068, 21 pages
http://dx.doi.org/10.1155/2011/569068
Review Article

Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy

1Department of Pathology, Amgen Inc., Thousand Oaks, CA 91320, USA
2GEMpath Inc., 2867 Humboldt Cir, Longmont, CO 80503, USA
3Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA 91320, USA
4Department of Inflammation, Amgen Inc., Thousand Oaks, CA 91320, USA
5Willamette Health Partners, Salem, OR 97301, USA
6HAMILTON Bonaduz AG, 7402 Bonaduz, Switzerland
7Department of Global Development, Amgen Inc., Thousand Oaks, CA 91320, USA
8EUROCBI GmbH, Benglen, 8121 Zurich, Switzerland

Received 10 September 2010; Accepted 20 October 2010

Academic Editor: Oreste Gualillo

Copyright © 2011 Brad Bolon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Brad Bolon, Marina Stolina, Caroline King, et al., “Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating Efficacy,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 569068, 21 pages, 2011. https://doi.org/10.1155/2011/569068.